Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MET exon 14 mutation
i
Other names:
DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4233
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
MET overexpression (32)
MET expression (12)
MET positive (8)
EGFR expression + MET expression (2)
MET overexpression + KDR overexpression (2)
MET overexpression + SYK overexpression (2)
TPBG expression + MET expression (2)
FGFR overexpression + MET overexpression (1)
MET expression + HER-2 expression (1)
MET overexpression + HER-2 overexpression (1)
MET overexpression + MUC5B overexpression (1)
MET underexpression (1)
PTGS2 positive + MET positive + TOPK positive + EGFR mutation (0)
MET overexpression (32)
MET expression (12)
MET positive (8)
EGFR expression + MET expression (2)
MET overexpression + KDR overexpression (2)
MET overexpression + SYK overexpression (2)
TPBG expression + MET expression (2)
FGFR overexpression + MET overexpression (1)
MET expression + HER-2 expression (1)
MET overexpression + HER-2 overexpression (1)
MET overexpression + MUC5B overexpression (1)
MET underexpression (1)
PTGS2 positive + MET positive + TOPK positive + EGFR mutation (0)
›
Related tests:
FoundationOne® CDx (110)
FoundationOne® Liquid CDx (21)
Droplex c-Met Exon14 Skipping Test
Lung Cancer 8-Gene Kit
FoundationOne® CDx (110)
FoundationOne® Liquid CDx (21)
Droplex c-Met Exon14 Skipping Test
Lung Cancer 8-Gene Kit
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
tepotinib
Sensitive: A1 - Approval
tepotinib
Sensitive
:
A1
tepotinib
Sensitive: A1 - Approval
tepotinib
Sensitive
:
A1
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
capmatinib
Sensitive: A1 - Approval
capmatinib
Sensitive
:
A1
capmatinib
Sensitive: A1 - Approval
capmatinib
Sensitive
:
A1
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
savolitinib
Sensitive: A1 - Approval
savolitinib
Sensitive
:
A1
savolitinib
Sensitive: A1 - Approval
savolitinib
Sensitive
:
A1
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
APL-101
Sensitive: A1 - Approval
APL-101
Sensitive
:
A1
APL-101
Sensitive: A1 - Approval
APL-101
Sensitive
:
A1
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
gumarontinib
Sensitive: A1 - Approval
gumarontinib
Sensitive
:
A1
gumarontinib
Sensitive: A1 - Approval
gumarontinib
Sensitive
:
A1
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
MET exon 14 mutation
Lung Adenocarcinoma
MET exon 14 mutation
Lung Adenocarcinoma
tepotinib
Sensitive: C1 - Off-label
tepotinib
Sensitive
:
C1
tepotinib
Sensitive: C1 - Off-label
tepotinib
Sensitive
:
C1
MET exon 14 mutation
Lung Adenocarcinoma
MET exon 14 mutation
Lung Adenocarcinoma
capmatinib
Sensitive: C1 - Off-label
capmatinib
Sensitive
:
C1
capmatinib
Sensitive: C1 - Off-label
capmatinib
Sensitive
:
C1
MET exon 14 mutation
Lung Adenocarcinoma
MET exon 14 mutation
Lung Adenocarcinoma
savolitinib
Sensitive: C1 - Off-label
savolitinib
Sensitive
:
C1
savolitinib
Sensitive: C1 - Off-label
savolitinib
Sensitive
:
C1
MET exon 14 mutation
Gastric Cancer
MET exon 14 mutation
Gastric Cancer
tepotinib
Sensitive: C1 - Off-label
tepotinib
Sensitive
:
C1
tepotinib
Sensitive: C1 - Off-label
tepotinib
Sensitive
:
C1
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
amivantamab-vmjw
Sensitive: C2 – Inclusion Criteria
amivantamab-vmjw
Sensitive
:
C2
amivantamab-vmjw
Sensitive: C2 – Inclusion Criteria
amivantamab-vmjw
Sensitive
:
C2
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
ensartinib
Sensitive: C2 – Inclusion Criteria
ensartinib
Sensitive
:
C2
ensartinib
Sensitive: C2 – Inclusion Criteria
ensartinib
Sensitive
:
C2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.